Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · IEX Real-Time Price · USD
2.350
-0.180 (-7.11%)
At close: Apr 24, 2024, 4:00 PM
2.360
+0.010 (0.43%)
Pre-market: Apr 25, 2024, 9:00 AM EDT
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $439.49 million as of April 25, 2024. Its market cap has increased by 791.47% in one year.
Market Cap
439.49M
Enterprise Value
352.41M
1-Year Change
791.47%
Ranking
Category
Stock Price
$2.35
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has decreased from $690.43M to $439.49M, a decrease of -36.34%. That is a compound annual growth rate of -11.84%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Apr 24, 2024 | 439.50M | -7.12% |
Apr 23, 2024 | 473.20M | 2.85% |
Apr 22, 2024 | 460.10M | 8.39% |
Apr 19, 2024 | 424.50M | -5.81% |
Apr 18, 2024 | 450.70M | -1.64% |
Apr 17, 2024 | 458.20M | -4.86% |
Apr 16, 2024 | 481.60M | -3.20% |
Apr 15, 2024 | 497.50M | -9.51% |
Apr 12, 2024 | 549.80M | -8.70% |
Apr 11, 2024 | 602.20M | 2.55% |
Apr 10, 2024 | 587.20M | 6.07% |
Apr 9, 2024 | 553.60M | 10.45% |
Apr 8, 2024 | 501.20M | - |
Apr 5, 2024 | 501.20M | - |
Apr 4, 2024 | 501.20M | -1.47% |
Apr 3, 2024 | 508.70M | 0.37% |
Apr 2, 2024 | 506.80M | -4.58% |
Apr 1, 2024 | 531.10M | -1.04% |
Mar 28, 2024 | 536.70M | -9.46% |
Mar 27, 2024 | 592.80M | 3.58% |
Mar 26, 2024 | 572.30M | - |
Mar 25, 2024 | 572.30M | -5.84% |
Mar 22, 2024 | 607.80M | 4.83% |
Mar 21, 2024 | 579.80M | 4.73% |
Mar 20, 2024 | 553.60M | 31.56% |
View and export this data all the way back to 2020.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
LifeMD | 449.27M |
Aveanna Healthcare Holdings | 448.24M |
KalVista Pharmaceuticals | 445.51M |
Editas Medicine | 444.48M |
Theravance Biopharma | 444.08M |
Oculis Holding AG | 440.16M |
ZimVie | 428.47M |
Avid Bioservices | 423.07M |